Corbus Pharmaceuticals (CRBP) Jefferies Global Healthcare Conference 2026 summary

Pipeline Overview and Clinical Progress

• Two lead assets: CRB-701 (Nectin-4 ADC) for oncology/solid tumors and CRB-913 (CB1 inverse agonist) for obesity, both in clinical development.

• Recent clinical data readouts for both programs, with additional data expected later in the year and early next year.

• CRB-701 granted FDA Fast Track for HNSCC and cervical cancer; advancing to registrational studies in 2L OPSCC and cervical cancer.

• CRB-913 targets obesity with a novel, peripherally restricted mechanism; Phase 1b dose-ranging study underway.

CRB-701 Clinical Data, Strategy, and Market Insights

• Phase I/II data in cervical cancer show a confirmed ORR in the mid-30% range, about double that of Tivdak, with DOR at 8+ months and PFS at 4+ months.

• In 2L+ OPSCC, 42.9% CORR and 85.7% DCR at 3.6 mg/kg, median DoR 6.3 months, PFS 5.6 months; strong efficacy in HPV-positive oropharyngeal patients.

• Safety profile notable for low severe peripheral neuropathy and manageable ocular toxicities; few discontinuations due to adverse events.

• FDA alignment for single registrational studies in cervical and oropharyngeal cancers, using physician's choice as control and accelerated approval based on interim response rates.

• Market opportunity: 14,000 eligible U.S. 2L oropharyngeal cancer patients annually, with HPV-positive incidence rising; cervical cancer program addresses a $1.8B US market.

Study Design and Competitive Landscape

• Registrational study for oropharyngeal cancer to start in summer, enrolling only oropharyngeal patients, with adaptive design to adjust sample size if needed.

• Study powered for 125 patients per arm, with expectations for control arm ORR in the mid to high teens.

• No other ongoing studies are enrolling oropharyngeal patients exclusively; EGFR bispecific competitors exclude or limit this group.

• Frontline study with KEYTRUDA aims to enroll about two dozen patients by early next year, focusing on efficacy and safety compared to PADCEV, but without high peripheral neuropathy rates.

• Registrational study in 2L OPSCC to launch summer 2026, targeting accelerated approval based on ORR and full approval on OS.